Updated Clinical Results and New Biomarker Analyses Presented for Daiichi Sankyo's DS-1062 in Patients with Advanced NSCLC at 2019 World Conference on Lung Cancer

Corporate Breaking News

Home : Updated Clinical Results and New Biomarker Analyses Presented for Daiichi Sankyo's DS-1062 in Patients with Advanced NSCLC at 2019 World Conference on Lung Cancer

Sep 10 2019	Updated Clinical Results and New Biomarker Analyses Presented for Daiichi Sankyo's DS-1062 in Patients with Advanced NSCLC at 2019 World Conference on Lung Cancer
TOKYO, MUNICH, and BASKING RIDGE, N.J., Sept. 10, 2019 /PRNewswire/ -- Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced the presentation of updated phase 1 clinical results and new biomarker data for DS-1062, an investigational TROP2 targeting antibody drug conjugate...


Source:https://www.prnewswire.com:443/news-releases/updated-clinical-results-and-new-biomarker-analyses-presented-for-daiichi-sankyos-ds-1062-in-patients-with-advanced-nsclc-at-2019-world-conference-on-lung-cancer-300914513.html

Related News
» Optus Selects Hughes JUPITER System to Enable Satellite Services throughout Australia » Updated Phase 1 Data for Daiichi Sankyo's U3-1402 in Patients with EGFR Mutated NSCLC Presented at 2019 World Conference on Lung Cancer